NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.83
  • Forecasted Upside: 110.62 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.82
▲ +0.13 (7.69%)

This chart shows the closing price for ZIOP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ZIOPHARM Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZIOP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZIOP

Analyst Price Target is $3.83
▲ +110.62% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for ZIOPHARM Oncology in the last 3 months. The average price target is $3.83, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 110.62% upside from the last price of $1.82.

This chart shows the closing price for ZIOP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in ZIOPHARM Oncology. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2021Lake Street CapitalLower Price TargetBuy$7.00 ➝ $3.50High
8/9/2021Raymond JamesDowngradeOutperform ➝ Market Perform$3.00High
5/10/2021HC WainwrightReiterated RatingHoldHigh
5/7/2021Raymond JamesLower Price TargetOutperform$5.50 ➝ $4.00High
3/18/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$7.00 ➝ $5.00High
3/12/2021Raymond JamesSet Price TargetOutperform$5.50High
3/12/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00 ➝ $5.00High
3/8/2021HC WainwrightReiterated RatingBuy ➝ NeutralHigh
3/1/2021HC WainwrightDowngradeBuy ➝ NeutralLow
2/26/2021Raymond JamesSet Price TargetOutperform$5.50High
11/20/2020Raymond JamesReiterated RatingBuy$5.50High
11/6/2020Raymond JamesSet Price TargetOutperform$5.50Low
9/15/2020Raymond JamesSet Price TargetOutperform$5.50Low
8/7/2020Raymond JamesSet Price TargetOutperform$5.50Low
7/10/2020Raymond JamesSet Price TargetOutperform$5.50Low
6/21/2020LaidlawReiterated RatingBuy$7.50High
6/21/2020Cantor FitzgeraldReiterated RatingOverweight ➝ Market Perform$6.00High
6/19/2020Jefferies Financial GroupInitiated CoverageBuy$7.00High
6/8/2020Cantor FitzgeraldReiterated RatingOverweightMedium
5/28/2020Raymond JamesSet Price TargetOutperform$5.50High
5/11/2020HC WainwrightReiterated RatingBuy$6.50 ➝ $5.50High
5/8/2020Raymond JamesSet Price TargetOutperform$5.50Low
3/3/2020Cantor FitzgeraldInitiated CoverageOverweight$6.00High
3/3/2020HC WainwrightReiterated RatingBuy$6.50Low
3/3/2020Raymond JamesLower Price TargetOutperform$6.50 ➝ $5.50High
1/17/2020Raymond JamesSet Price TargetOutperform$6.50High
12/10/2019Raymond JamesSet Price TargetOutperform$6.50Low
12/10/2019HC WainwrightReiterated RatingBuy$6.50High
11/25/2019Raymond JamesSet Price TargetOutperform$6.50High
11/8/2019Raymond JamesSet Price TargetOutperform$6.50High
10/29/2019Raymond JamesReiterated RatingOutperform$6.50Low
10/2/2019Raymond JamesSet Price TargetOutperform$6.50Low
10/2/2019HC WainwrightReiterated RatingBuy$6.50Low
8/22/2019Raymond JamesInitiated CoverageOutperform$6.50High
5/9/2019HC WainwrightReiterated RatingBuy$5.50Medium
4/4/2019Lake Street CapitalInitiated CoverageBuy ➝ Buy$7.00Medium
4/1/2019LaidlawInitiated CoverageBuy ➝ Buy$7.50High
11/15/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$5.00Medium
11/13/2018HC WainwrightSet Price TargetBuy$6.00High
6/18/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
5/14/2018HC WainwrightReiterated RatingBuy$5.50Low
3/5/2018HC WainwrightSet Price TargetBuy$10.00High
12/14/2017HC WainwrightSet Price TargetBuy$10.00Medium
12/11/2017Raymond JamesReiterated RatingHoldHigh
11/7/2017HC WainwrightReiterated RatingBuy$9.50N/A
8/1/2017HC WainwrightSet Price TargetBuy$10.00Medium
6/1/2017HC WainwrightInitiated CoverageBuy ➝ Buy$9.50High
2/28/2017Griffin SecuritiesReiterated RatingBuy$23.00N/A
2/10/2017Griffin SecuritiesReiterated RatingBuy$21.00 ➝ $23.00N/A
1/12/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
11/19/2016Griffin SecuritiesReiterated RatingBuy$21.00N/A
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021

Current Sentiment

  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
ZIOPHARM Oncology logo
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $1.82
Low: $1.68
High: $1.85

50 Day Range

MA: $1.98
Low: $1.44
High: $2.47

52 Week Range

Now: $1.82
Low: $1.26
High: $5.95

Volume

5,332,200 shs

Average Volume

2,648,127 shs

Market Capitalization

$392.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of ZIOPHARM Oncology?

The following Wall Street sell-side analysts have issued stock ratings on ZIOPHARM Oncology in the last year: HC Wainwright, Jefferies Financial Group Inc., Lake Street Capital, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for ZIOP.

What is the current price target for ZIOPHARM Oncology?

3 Wall Street analysts have set twelve-month price targets for ZIOPHARM Oncology in the last year. Their average twelve-month price target is $3.83, suggesting a possible upside of 110.6%. Jefferies Financial Group Inc. has the highest price target set, predicting ZIOP will reach $5.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $3.00 for ZIOPHARM Oncology in the next year.
View the latest price targets for ZIOP.

What is the current consensus analyst rating for ZIOPHARM Oncology?

ZIOPHARM Oncology currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ZIOP, but not buy more shares or sell existing shares.
View the latest ratings for ZIOP.

What other companies compete with ZIOPHARM Oncology?

How do I contact ZIOPHARM Oncology's investor relations team?

ZIOPHARM Oncology's physical mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company's listed phone number is (617) 259-1970 and its investor relations email address is [email protected] The official website for ZIOPHARM Oncology is www.ziopharm.com.